Related references
Note: Only part of the references are listed.Hemophilia therapy: the future has begun
Pier Mannuccio Mannucci
HAEMATOLOGICA (2020)
Bispecific antibody activated T cells: A newly developed T cells with enhanced proliferation ability and cytotoxicity
Qingming Guo et al.
IMMUNOLOGY LETTERS (2020)
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Paul J. Carter et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Guangmin Li et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects
Hao Yang et al.
THERANOSTICS (2018)
Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies
Joerg U. Schmohl et al.
TOXINS (2018)
Moxetumomab Pasudotox: First Global Approval
Sohita Dhillon
DRUGS (2018)
Decreased IFIT2 Expression Promotes Gastric Cancer Progression and Predicts Poor Prognosis of the Patients
Lujun Chen et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Targeted Delivery to Tumor-associated Pericytes via an Affibody with High Affinity for PDGFRβ Enhances the in vivo Antitumor Effects of Human TRAIL
Ze Tao et al.
THERANOSTICS (2017)
PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer
Qiuxiao Shi et al.
DRUG DELIVERY (2017)
Evolution of anti-HER2 therapies for cancer treatment
Sagun Parakh et al.
CANCER TREATMENT REVIEWS (2017)
Affibody molecules as engineered protein drugs
Fredrik Y. Frejd et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2017)
Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer
L. Tiffany Lyle et al.
CLINICAL CANCER RESEARCH (2016)
Fusion of an albumin-binding domain extends the half-life of immunotoxins
Rui Guo et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Advances in Anticancer Immunotoxin Therapy
Christine Alewine et al.
ONCOLOGIST (2015)
A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties
Felix Unverdorben et al.
PLOS ONE (2015)
Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria
Michael-Paul Robinson et al.
NATURE COMMUNICATIONS (2015)
PDGF receptors in tumor biology: prognostic and predictive potential
Janna Paulsson et al.
FUTURE ONCOLOGY (2014)
Imaging of Platelet-Derived Growth Factor Receptor β Expression in Glioblastoma Xenografts Using Affibody Molecule 111In-DOTA-Z09591
Vladimir Tolmachev et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
The immune system and response to HER2-targeted treatment in breast cancer
Giampaolo Bianchini et al.
LANCET ONCOLOGY (2014)
A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma
Nate N. Waldron et al.
TARGETED ONCOLOGY (2014)
SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection
Laura Vidalino et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2012)
HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors
Rafal Zielinski et al.
CLINICAL CANCER RESEARCH (2011)
Engineered High-Affinity Affibody Molecules Targeting Platelet-Derived Growth Factor Receptor β In Vivo
M. Lindborg et al.
JOURNAL OF MOLECULAR BIOLOGY (2011)
Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer
Janna Paulsson et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer
Brad J. Stish et al.
CLINICAL CANCER RESEARCH (2007)
The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer
A. E. Roussidis et al.
CURRENT MEDICINAL CHEMISTRY (2007)
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Share Paper
